Evidence map›Paper›PMID 38039505›Full record

ArticleJournal of medicinal chemistry2023

Discovery of Inhibitory Fragments That Selectively Target Spire2-FMN2 Interaction.

Radoslaw Kitel, Ewa Surmiak, Jan Borggräfe, Justyna Kalinowska-Tluscik, Przemyslaw Golik, Miroslawa Czub, Wiktor Uzar, Bogdan Musielak, Mariusz Madej, Grzegorz M Popowicz and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Radoslaw KitelFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kracow, Poland.ORCID 0000-0003-4718-8082
Ewa SurmiakFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kracow, Poland.ORCID 0000-0002-4103-4675
Jan BorggräfeInstitute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Neuherberg, 85764 München, Germany.
Justyna Kalinowska-TluscikFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kracow, Poland.
Przemyslaw GolikFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kracow, Poland.
Miroslawa CzubFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kracow, Poland.
Wiktor UzarFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kracow, Poland.ORCID 0000-0001-5770-105X
Bogdan MusielakFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kracow, Poland.ORCID 0000-0002-1665-5920
Mariusz MadejFaculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Cracow, Poland.
Grzegorz M PopowiczInstitute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Neuherberg, 85764 München, Germany.
Grzegorz DubinMalopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, 30-387 Krakow, Poland.ORCID 0000-0002-5535-5760
Tad A HolakFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kracow, Poland.ORCID 0000-0001-9369-6024
Jagiellonian University · PLHelmholtz Zentrum München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we report the fragment-based drug discovery of potent and selective fragments that disrupt the Spire2-FMN2 but not the Spire1-FMN2 interaction. Hit fragments were identified in a differential scanning fluorimetry-based screen of an in-house library of 755 compounds and subsequently validated in multiple orthogonal biophysical assays, including fluorescence polarization, microscale thermophoresis, and

Indexed as

Drug DiscoveryLigandsMolecular Docking SimulationLigands

Identifiers

PMID38039505
PMCPMC10726347
OpenAlexW4389234902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.